Although it has been known for more than 60 years that the cause of sickle cell disease is polymerization of a hemoglobin mutant, hydroxyurea is the only drug approved for treatment by the US Food and Drug Administration. This drug, however, is only partially successful, and the discovery of additional drugs that inhibit fiber formation has been hampered by the lack of a sensitive and quantitative cellular assay. Here, we describe such a method in a 96-well plate format that is based on laser-induced polymerization in sickle trait cells and robust, automated image analysis to detect the precise time at which fibers distort ("sickle") the cells. With this kinetic method, we show that small increases in cell volume to reduce the hemoglobin concentration can result in therapeutic increases in the delay time prior to fiber formation. We also show that, of the two drugs (AES103 and GBT440) in clinical trials that inhibit polymerization by increasing oxygen affinity, one of them (GBT440) also inhibits sickling in the absence of oxygen by two additional mechanisms.
Although it has been known for more than 60 years that the cause of sickle cell disease is polymerization of a hemoglobin mutant, hydroxyurea is the only drug approved for treatment by the US Food and Drug Administration. This drug, however, is only partially successful, and the discovery of additional drugs that inhibit fiber formation has been hampered by the lack of a sensitive and quantitative cellular assay. Here, we describe such a method in a 96-well plate format that is based on laser-induced polymerization in sickle trait cells and robust, automated image analysis to detect the precise time at which fibers distort ("sickle") the cells. With this kinetic method, we show that small increases in cell volume to reduce the hemoglobin concentration can result in therapeutic increases in the delay time prior to fiber formation. We also show that, of the two drugs (AES103 and GBT440) in clinical trials that inhibit polymerization by increasing oxygen affinity, one of them (GBT440) also inhibits sickling in the absence of oxygen by two additional mechanisms.
sickle cell | drugs | hemoglobin S | treatment | screening assay T here is currently only one specific drug being used to treat sickle cell disease (1) (2) (3) , despite the fact that a therapeutic target has been known since Pauling's discovery in 1949 that a mutation of the hemoglobin molecule is responsible (4) . Sickle hemoglobin (HbS) polymerizes upon deoxygenation to form fibers that stiffen and distort ("sickle") the red cells. Occlusion of narrow vessels of the tissues by the less deformable cells reduces oxygen delivery, which damages multiple organs and causes episodes so painful that they are called "sickle cell crises." Although accurate statistics are lacking, it is estimated that several million people worldwide suffer from sickle cell disease, with the vast majority in Third-World countries (5) . The disease can be cured by stem cell transplantation, which is appropriate for the most severely ill patients with a matched sibling donor, but can be implemented only at advanced medical facilities (6) . Moreover, promising new curative methods, such as gene replacement or gene editing (7), even if eventually successful, will only be available for a small fraction of patients for many years. The one drug currently approved by the US Food and Drug Administration is hydroxyurea, which is only partially successful (8, 9) . Consequently, what is urgently needed is a drug in addition to hydroxyurea that inhibits polymerization, the root cause of the disease. To make it available worldwide, the drug should be one that can be taken orally and is very inexpensive. Here, we describe a sensitive and quantitative assay that is directly connected to pathogenesis ( Fig. 1) and can be used to screen for inhibition of fiber formation inside cells.
Our assay is based on the highly unusual kinetics of polymerization characterized by a delay period before fiber formation that is enormously sensitive to the intracellular HbS concentration and on the recognition that a major determinant of clinical severity is whether the delay time is longer or shorter than the transit time through the narrow vessels of the tissues (14) (15) (16) (Fig. 1) . Hydroxyurea is therapeutic because it induces the synthesis of fetal hemoglobin (HbF) (17, 18) , which inhibits polymerization by reducing the HbS concentration to markedly increase delay times and allow more red cells to escape to larger vessels before fibers form (19, 20) . However, hydroxyurea does not act on all cells, which reduces its efficacy (8, 9, 21, 22) , so there is considerable effort to discover targets and eventually develop drugs that will induce HbF synthesis in every cell (23) . The search for a drug that inhibits fiber formation in all cells, other than by altering hemoglobin synthesis, has been hampered by the lack of a screening assay that can be performed on cells. Our assay accurately and sensitively tests for inhibition of intracellular polymerization in a 96-well plate format by measuring sickling time distributions in cells from patients with sickle cell trait, the heterozygous condition. Polymerization is induced by photodissociation of the hemoglobin-carbon monoxide complex (HbCO) with a continuous wave (cw) laser to rapidly create and maintain hemoglobin in the deoxy form that polymerizes to form fibers. Fibers are detected as alterations in red cell morphology by using a unique and robust image-analysis algorithm. Using this assay, we have discovered powerful polymerization inhibitors that act by producing small increases in cell volume to decrease the intracellular hemoglobin concentration, indicating that increasing cell volume is a viable approach to therapy. We also show that one (GBT440) of the two Significance Sickle cell disease can be treated by preventing polymerization of the mutant hemoglobin to form fibers during the time that red cells are transiting the smallest vessels of the tissues. However, most drugs in clinical trials are aimed at reducing the sequelae of fiber formation, such as inflammation and adhesion to the vascular endothelium. Searching for drugs that increase the delay before polymerization, which allows more cells to escape the small vessels before fibers form, has been hampered by the lack of a quantitative and sensitive assay, which we describe in this work. With this assay, we show that increasing the delay time by increasing red cell volume to reduce the intracellular hemoglobin concentration is a viable approach to therapy.
oxygen affinity modifiers currently in clinical trials inhibits polymerization in completely deoxygenated cells, albeit at concentrations too high for treating patients, but might be modified to add therapeutic benefit.
Results
Rationale for Screening with Sickle Trait Cells. The use of cells addresses the very important question of penetration of the red cell membrane by a potential drug. It also allows the detection of drugs that increase sickling times by several different methods, including decreasing the intracellular hemoglobin concentration by increasing cell volume, blocking intermolecular contacts in the fiber, or weakening contacts, for example, by increasing intracellular pH (24) or by decreasing 2,3-diphosphoglycerate synthesis (25) . There are many advantages to using cells from donors with sickle cell trait (AS), the heterozygous condition, rather than cells from patients with homozygous sickle cell (SS) disease. (i) Sickle trait is a benign condition and far more prevalent (∼8% of African Americans) than sickle cell disease, so that blood samples are much more readily available. Moreover, many sickle trait patients have relatives with sickle cell disease, so they are more than willing to donate blood samples as frequently as requested. (ii) The sickle trait cell population is much more homogeneous, and therefore the interpretation of results is more straightforward. The cell population is more homogeneous because trait cells sickle very much less frequently in vivo and so incur relatively little or no damage compared with SS cells, which undergo many sickling/unsickling cycles (15, 26) . The large dilution of HbS by normal hemoglobin (HbA) in trait cells increases the sickling time by several orders of magnitude without changing the mechanism of fiber formation (13, (27) (28) (29) (30) . Even though there is less fiber formation in sickle trait cells, the longer delay times produce larger distortions than observed for deoxygenated SS cells, making it easier for image analysis to accurately determine sickling times. Larger distortions occur because there are fewer homogeneously nucleated fibers and therefore fewer domains of fibers (31) . The longer sickling times (27) compared with SS cells (20, 32) also allow a much lower cw laser power density to maintain complete photodissociation of the HbCO complex. With the lower power density, a defocused laser beam and larger field of view can be used for simultaneous observation of many cells (up to 200), compared with one cell at a time in previous photolysis experiments with SS cells (20, 32) .
Sample Preparation and Measurement of Sickling Times. The main consideration in preparing samples is to obtain cells with hemoglobin as the CO complex in a near physiological buffer in a 96-well plate at 37°C in the complete absence of oxygen. CO is used instead of oxygen because the HbCO complex is much more readily photodissociated than the oxygen complex. All oxygen must be eliminated because it would bind to hemoglobin very rapidly while the cells are being illuminated by the laser and artifactually increase the sickling time. The procedure consists of adding the candidate drug to wells containing a dilute suspension of CO-saturated sickle trait cells, sealing the well plate to prevent loss of CO, placing the plate in a 37°C incubator purged with humidified nitrogen for either 4 or 24 h, unsealing the well plate under a nitrogen atmosphere, and adding sodium dithionite to remove any traces of oxygen. The well plate is then resealed and transferred to the microscope and mounted on an xy translation stage for well-by-well sickling time measurements at 37°C.
Fiber formation is induced by photodissociating the CO from hemoglobin with a cw argon ion laser operating at 514 nm to rapidly (∼0.2 s) form and maintain close to 100% deoxyhemoglobin. Images of the cells are recorded by a CCD camera at 100-ms intervals for 5 s before illumination with the laser and for 60 s thereafter, which is sufficiently long to sickle more than ∼60% of cells, which contain an ∼60/40 HbA/HbS mixture. A complete well-plate experiment consists of a sequence of such photolysis experiments performed on the wells in a specified order. The entire experiment is performed under computer control by using LABVIEW (National Instruments). This software controls the sequence in which the wells are imaged by moving an xy stage on which the well plate is mounted, as well as the gating of laser illumination and the input and storage of the set of camera images for each well.
Although nitrogen is flowed over the sealed well plate, we have not been able to find a transparent material that makes a seal that is completely impermeable to oxygen. Consequently, the duration of the sickling time measurements for 96 wells is limited to 3-4 h because of eventual oxygen leaks. Additional details of sample preparation and the apparatus (SI Appendix, Fig. S1 ) are given in SI Appendix. (Fig. 2) and saved as JPEG files. To establish grayscale ranges, analysis is first conducted on images at 0.1 s after photolysis, when hemoglobin is almost completely in the deoxy form and no cells have sickled. Pixel values for all images are transformed to maximize the dynamic range of the values, followed by assigning each pixel to either a cell or background (see SI Appendix for details). Based on this classification, a list of cells, defined as contiguous regions of pixels of density above a background threshold, is compiled. Regions too small to represent a red cell are removed, as are regions too large to be processed, such as two or more individual cells that overlap. The set of pixels (10), the delay time at in vivo oxygen pressures is sufficiently long that the vast majority of cells escape the microcirculation before sickling has occurred. (C ) Cartoon showing that, if the delay time is sufficiently short or disappears because the intracellular HbS concentration is so high that fibers or seeds remain even after oxygenation in the lungs (11), then sickling can occur in the microcirculation, and the cell becomes much less flexible, introducing the possibility of vaso-occlusion by producing a "log jam" of cells. Cells that escape (B) and sickle in the larger vessels rapidly unsickle upon oxygenation in the lungs. Increasing the delay time or shortening the transit time through the microcirculationfor example, by decreasing the adherence of cells to the vessel walls (12)-should therefore decrease clinical severity. If the system were at equilibrium, all cells would be sickled at tissue oxygen pressures (10) , and the disease would not be survivable after fetal hemoglobin is replaced by HbS (13).
assigned to each remaining cell is tracked, which allows cells to be monitored even if they move during the 65-s observation period.
The determination of the sickling time is based on the reasoning that fiber formation is the only possible cause of even the slightest cellular distortion. Moreover, previous studies on laser photolysisinduced polymerization showed that distortion of SS cells is simultaneous with the onset of increased light scattering (10) . Three metrics describing cell morphology are computed for all 650 images of each cell before and after the start of laser illumination. These are the projected area of the cell (the number of pixels assigned to a cell), the ratio of the density on the periphery of the cell to the center (unsickled cells are biconcave discs, which are more transparent in the center; Figs. 2 and 3) , and the deviation from a circular shape as determined by the eccentricity (the ratio of the longest to the shortest dimension of the cell). The time at which there are simultaneous changes in at least two of these three metrics is taken as the sickling time, which can be precisely determined as shown in Fig. 3A . There is a wide distribution of sickling times (Figs. 3B and 4 and SI Appendix, Fig. S4F ) caused primarily by the variation in intracellular hemoglobin concentration (see below and SI Appendix, Fig. S4A) (Fig. 3C) ]. Also shown in Fig. 3C is the cumulant calculated from the intracellular concentration distribution and the solubility of mixtures of HbA and HbS (see SI Appendix, SI Text and Fig. S4 for description of calculation) . The good agreement with the experimental result indicates that there is little or no difference between polymerization in cells and in solutions of purified hemoglobins. SI Appendix, Fig. S2 shows the cumulant of the sickling time distributions for blood from five sickle trait donors. A movie of cell images is shown in Movie S1.
Criteria for Therapeutic Inhibition. A relatively unique feature of sickle cell disease is that it is possible to take advantage of our understanding of the kinetics and thermodynamics of fiber formation and the known correlation between clinical severity and red cell composition to predict the potential therapeutic effect from the measured increases in sickling times in our assay (13, 20, 29, 35) . Previous analyses (13, 35) did not consider the distribution of intracellular concentrations and solubilites, which produces a very large distribution of sickling times for cells having the same hemoglobin composition. The longer delay times in trait cells Fig. 2 . Representative images of red cells before photolysis (−5 s) and at 0.2, 10, and 60 s after initiating cw photolysis (Movie S1). The contrast is less at −5 s because the absorption maximum of HbCO is 419 nm, whereas that of deoxy Hb is 430 nm, which corresponds to the wavelength of maximum transmission of the bandpass filter. At +0.2 s, no cells have sickled; 50% are sickled at +10 s, and 71% are sickled at +60 s. Data from the analysis of the cells circled in white is shown in Fig. 3 .
compared with SS cells result in greater sensitivity to changes in intracellular concentration and composition. Consequently, our problem is to relate the inhibitory effects in trait cells to those in SS cells. The key to making this connection is the recent discovery of a universal relation between the delay time and the supersaturation (the concentration divided by the solubility, with both being multiplied by an activity coefficient) (SI Appendix, Fig. S4E ; ref. 33) for purified hemoglobin solutions, which allows us to calculate the delay time at any concentration and solubility (see SI Appendix for details of these calculations).
Two sickle syndromes are particularly useful for our analysis. One is sickle cell disease with pancellular hereditary persistence of fetal hemoglobin (S/HPHF), in which all cells contain ∼30% HbF and ∼70% HbS (8) . Patients with S/HPHF "have symptoms of neither sickle cell disease nor hemolytic anemia" (8) . A drug that increases sickling times in trait cells comparable to that expected for cells in which 30% of the HbS/HbA mixture has been replaced by HbF is therefore regarded as "potentially curative." The second is hemoglobin SC disease. SC cells contain ∼50% HbS and ∼50% HbC, which has the same effect on fiber formation as HbA (36) . In Fig. S3 ), and solubilities at each concentration of the concentration distribution from SI Appendix, Eq. S1 by using a hemoglobin composition of 38% HbS and 62% HbA (the composition for this patient is 38% HbS, 58% HbA, 3.7% HbA 2 , and 0.3% HbF). Importantly, it is assumed that every cell has the same hemoglobin composition.
addition to containing a higher fraction of HbS than trait cells, SC cells have a greater total Hb concentration, explaining why it is a severe sickle syndrome, albeit less severe than homozygous SS disease (36, 37) . A drug that increases sickling times in trait cells comparable to that expected for cells in which 50% of the HbS/HbA mixture has been replaced by HbA (=HbC) and the intracellular concentrations increased by 10%, is regarded as "potentially therapeutic." From these calculations (Fig. 4) , which are described in detail in SI Appendix, Fig. S5 , we conclude that compounds for which no sickling occurs at 60 s are potentially curative, whereas compounds for which the percent sickled is 30% relative to the control (absence of the compound) are potentially therapeutic. Given the uncertainties in the calculation, in the subsequent discussion we shall regard 10% sickling at 60 s, compared with the control with no drug, as potentially curative and 60% as potentially therapeutic. Despite the fact that the calculations are only approximate, they serve as an extremely useful guide for assessing therapeutic potential. (There are, of course, many additional factors to be considered for evaluating therapeutic efficacy, including toxicity, binding to plasma proteins, pharmacokinetics, bioavailability, etc.)
Discovery of Powerful Inhibitors that Increase Cell Volume. Because there is a large amount of hemoglobin (almost 1 pound) in the average adult sickle cell patient, the amount of drug that acts by noncovalent binding to HbS is expected to be intolerably large. Conversely, decreasing the intracellular hemoglobin concentration by increasing cell volume using compounds that bind to the red cell membrane should require much less. One such class of compounds is ionophores, which were suggested many years ago (38) . We therefore first carried out a simple and truly high throughput prescreen of the 1,600-compound "Pharmakon Collection" (Microsource Discovery Systems), which contains a large number of clinically tested compounds, to search for compounds that sphere red cells. Sphered red cells are easily detected because they have a smaller diameter and an increased density at the center of the cell compared with normal biconcave discs (SI Appendix, Fig. S6 ). Compounds that sphere cells are those that are also expected to increase cell volume at subsphering concentrations. The volume of sphered cells is ∼1.7-fold larger than a biconcave disk. This increase in the cell volume reduces the intracellular hemoglobin concentration of all trait cells to <0.23 g/mL, so they will never sickle because the supersaturation is <1.0 (SI Appendix, Fig. S4 A and C) , or the supersaturation is so low (SI Appendix, Fig. S4E ) that sickling will take much longer than 60 s; we have never observed sphered cells to change shape (i.e., sickle) after 60 s of laser photolysis. Two compounds that swell cells and are powerful inhibitors at subsphering concentrations are the ionophores gramicidin A and monensin A (Fig. 5) . Both compounds show inhibition that increases with incubation time. After a 4-h incubation, monensin has no therapeutically significant effect on sickling times at concentrations less than ∼6 nM (Fig. 5, Lower) , whereas, after a 24-h incubation, threshold inhibition is observed at a concentration of ∼2 nM, and at a concentration of 6 nM, it achieves a level of inhibition expected for a potentially curative drug (Fig. 4) . As expected from the sphering prescreen, monensin acts by increasing cell volume (Fig. 5, Upper) , indicating that dilution of intracellular hemoglobin is the inhibitory mechanism. In previous studies of the effect of monensin on cell volume and other cellular properties, not including sickling, the effects of concentrations <10 nM were not investigated (38) .
Gramicidin A also acts by slowly increasing cell volume, but produces larger volume increases and correspondingly longer sickling times at much lower concentrations (Fig. 5, Lower) . Inhibition comparable to our therapeutically significant threshold of 60% sickled compared with control is observed after 4 h at concentrations as low as ∼200 pM, and almost no sickling is observed at 60 s at a concentration of 800 pM, corresponding to a potentially curative drug (Fig. 4) . After 24 h of incubation at a concentration of 100 pM, there is only 10% sickling at 60 s. As expected from the sphering prescreen, gramicidin A increases cell volume (Fig. 5, Upper) , again indicating that dilution of intracellular hemoglobin is the inhibitory mechanism.
Additional data for the effect of both compounds on fraction sickled and volume in different donors is given in SI Appendix, Figs. S7 and S8. A potentially serious toxic side effect of compounds that increase cell volume is hemolysis. However, no significant hemolysis was observed at therapeutically-significant inhibitory concentrations (i.e., <10 nM for monensin and <800 pM for gramicidin; SI Appendix, Fig. S9 ).
Inhibition by Oxygen Affinity Modifiers. There are only two compounds currently in clinical trials for the treatment of sickle cell disease that act by inhibiting polymerization. One is 5-hydroxymethyl-2-furfural (called AES-103; ClinicalTrials.gov identifier NCT019879080) (39) . The other is 2-hydroxy-6((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde) (called GBT440; ClinicalTrials.gov identifier NCT02285088; ref. 40) . Both compounds are believed to inhibit sickling in vivo primarily by increasing oxygen affinity because of preferential binding to the high-affinity R quaternary structure, which does not enter the fiber (13, 29) (SI Appendix, Fig. S10 ). The question has remained whether there is any additional inhibitory effect on intracellular fiber formation other than that resulting from shifting the T-R quaternary equilibrium toward R (39). Fig. 6 shows volume and sickling time measurements over a range of concentrations from 100 nM to 3 mM. AES103 shows no significant antisickling effect up to a concentration of 3 mM. In contrast, GBT440 shows therapeutically significant inhibition at concentrations >30 μM. The Coulter Counter volume data (Fig. 6 , Upper and SI Appendix, Fig. S8 ) indicate that the inhibitory effect for a 24-h incubation results from a volume increase, whereas inhibition at 4 h does not.
Discussion
Basic biophysical studies have suggested four approaches to therapeutic inhibition of HbS polymerization (13, 20, 29) R quaternary structure; and (iv) weaken fiber contacts by altering intracellular conditions such as pH and/or 2,3-diphosphoglycerate concentration. [Decreasing the concentration of 2,3-diphosphoglycerate inhibits polymerization by two mechanisms-increasing oxygen affinity and increasing solubility of HbS (25) .] Highthroughput screens have been developed for the induction of HbF (42) (43) (44) (45) (46) . The only high-throughput screen for antipolymerization compounds up until now tests for increasing oxygen affinity on isolated hemoglobin solutions, but it does not address the question of cell permeability (47) .
The probability of discovering a drug is much higher if it inhibits polymerization by acting on a target that is much less abundant than hemoglobin, such as the red cell membrane or membrane proteins, which could result in an increase in cell volume to take advantage of the enormous concentration dependence of the delay time (48, 49) . A prescreen for compounds that swell cells to the extent that they sphere is high-throughput, which can then be followed with our slower, but more relevant, sickling time assay that is also directly connected to pathogenesis (Fig. 1) . We discovered two compounds that sphere red cells at nanomolar concentrations and are powerful inhibitors (Figs. 5 and 6 and SI Appendix, Fig. S7 ) at concentrations that do not sphere or hemolyse red cells (SI Appendix, Fig. S6 and S9 ). Our analysis of the quantitative criteria for therapeutic inhibition indicates that, if free concentrations of 100 pM gramicidin A and 4 nM monensin A could be achieved in the plasma, a major therapeutic effect would be achieved. Although neither compound has been tested in humans, and much work would be required to develop either into a drug, our experiments indicate that increasing the volume of red cells is a viable approach to therapy. Because toxicity is often the biggest stumbling block in drug development, our future studies with this assay will focus on compounds that have already been clinically tested. Compounds known to be nontoxic at concentrations that are active in our assay are immediate candidates for clinical trials.
Two drugs that increase oxygen affinity, AES103 and GBT440, are currently in clinical trials (Fig. 6 and SI Appendix, Figs. S7 and S10). Sunshine et al. showed that only the low-affinity T quaternary structure of hemoglobin polymerizes (50) . Consequently, a compound that preferentially binds to the high-affinity R quaternary structure shifts the T-R equilibrium toward the nonpolymerizing R structure and reduces sickling at tissue oxygen pressures. A decrease in the p50 by as little as 4-7 torr was predicted to be therapeutic (13) . To determine whether AES103 or GBT440 increases sickling times in the absence of oxygen, we tested both oxygen-affinity modifiers with our assay. For AES103, there are no published data on the concentrations of the drug in the serum of patients in clinical trials to assess its therapeutic efficacy. In phase 1 trials, the highest plasma concentration reported is 6 μM (51). AES103 has no therapeutically significant inhibitory effect in our assay up to a concentration of 3 mM (Fig. 6 and SI Appendix, Figs. S7 and S8), indicating that its only potential effect on sickling could come from increasing oxygen affinity, albeit at plasma concentrations much higher than 6 μM of the drug (SI Appendix, Fig. S10 ) (52). Our results for GBT440 are quite different. The maximum of the therapeutic range corresponds to 40% of the hemoglobin with drug bound (41) . From an analysis of the oxygen-binding curves (SI Appendix, SI Text and Fig. S12 ), we found that 40% modification occurs at 9 ± 1 μM GBT440. At concentrations >30 μM, there is therapeutically-significant inhibition of sickling in our assay after a 4-h incubation without a volume change and after a 24-h incubation with a volume change (Fig. 6 and SI Appendix, Fig. S7 ). At a concentration of 30 μM, the increase in oxygen affinity is much too large (SI Appendix, Fig. S10 ) and would prevent oxygen delivery to the tissues. However, our results do suggest that it would be worthwhile to modify GBT440, with the possibility of inhibiting sickling by three different biophysical mechanisms, which could significantly improve its therapeutic efficacy (53) . 
